Innophore GmbH Company Profile

Background

Overview

Innophore GmbH, founded in 2017 and headquartered in Graz, Austria, specializes in enzyme and drug discovery within the biotechnology and pharmaceutical sectors. The company leverages artificial intelligence (AI) and point-cloud technology to identify and optimize protein candidates for various applications, aiming to accelerate research and development pipelines for its clients.

Mission and Vision

Innophore's mission is to revolutionize protein and drug discovery by providing AI-powered solutions that enhance the efficiency and effectiveness of R&D processes. Their vision is to create a world where technology serves as a force for good—open, ethical, and designed to empower rather than exploit. They emphasize interoperability, transparency, and human-centered design in building adaptable solutions that create lasting value.

Industry Significance

Innophore operates at the intersection of biotechnology and artificial intelligence, addressing the growing need for innovative solutions in drug discovery and enzyme engineering. By integrating AI with structural biology, the company contributes to more efficient and targeted therapeutic developments, positioning itself as a significant player in the biotech industry.

Key Strategic Focus

Core Objectives

• Accelerate R&D Processes: Utilize AI and point-cloud technology to expedite the identification and optimization of protein candidates.

• Enhance Drug Discovery: Provide tools that support drug repurposing and the development of novel therapeutics.

• Promote Sustainable Practices: Advance green chemistry through enzyme engineering to support environmentally friendly chemical production.

Areas of Specialization

• Enzyme Discovery: Identifying novel enzymes for industrial biocatalysis applications.

• Drug Repurposing: Exploring new therapeutic applications for existing drugs using structural analysis.

• Structural Bioinformatics: Employing AI-driven analysis of protein structures to predict characteristics and reactivity.

Key Technologies Utilized

• Catalophore™ Platform: An AI-powered point-cloud technology that represents protein binding sites in three dimensions, enabling accurate protein cavity matching beyond sequence similarity.

• Deep Learning Models: Trained on millions of protein structures to provide novel insights into protein interactions and functionalities.

• High-Performance Computing: Utilizing supercomputing resources, including clusters with approximately 6,500 CPUs and cloud services such as AWS and Google Cloud, to run complex experiments.

Primary Markets Targeted

• Biotechnology: Companies involved in enzyme engineering and biocatalysis.

• Pharmaceuticals: Organizations focused on drug discovery, development, and repurposing.

• Chemical Industry: Firms seeking sustainable and efficient chemical production processes.

Financials and Funding

Funding History

Innophore has undergone multiple seed funding rounds, with the most recent occurring in 2020. The company has been funded by Markus Wagner, who has been involved in all funding rounds.

Total Funds Raised

Specific details regarding the total funds raised are not publicly disclosed.

Notable Investors

• Markus Wagner: An investor who has supported Innophore through multiple funding rounds.

Utilization of Capital

The raised capital is primarily utilized for:

• Technology Development: Enhancing the Catalophore™ platform and other AI-driven tools.

• Research and Development: Expanding enzyme and drug discovery capabilities.

• Operational Expansion: Scaling operations to meet the needs of a growing client base.

Pipeline Development

Key Pipeline Candidates

Innophore's pipeline includes:

• Enzyme Candidates: Novel enzymes identified for industrial biocatalysis applications.

• Drug Repurposing Targets: Existing drugs being evaluated for new therapeutic applications.

Stages of Development

• Enzyme Discovery: Ongoing identification and optimization of enzyme candidates.

• Drug Repurposing: Structural analysis and validation of new therapeutic applications for existing drugs.

Target Conditions

• Industrial Applications: Enzymes for sustainable chemical production.

• Therapeutic Areas: Various diseases and conditions targeted through drug repurposing efforts.

Anticipated Milestones

• Short-Term: Completion of initial validation studies for enzyme candidates.

• Medium-Term: Advancement of drug repurposing projects into preclinical or clinical stages.

• Long-Term: Commercialization of enzyme products and therapeutic applications.

Technological Platform and Innovation

Proprietary Technologies

• Catalophore™ Platform: An AI-driven point-cloud technology that enables accurate protein cavity matching beyond traditional sequence similarity methods.

Significant Scientific Methods

• 3D Point-Cloud Representation: Utilizing three-dimensional models to represent protein binding sites, facilitating precise analysis of protein interactions.

• Deep Learning Models: Employing AI models trained on extensive protein structure datasets to predict protein characteristics and reactivity.

Leadership Team

Key Executives

• Dr. Christian Gruber: Chief Executive Officer (CEO).

• Dr. Georg Steinkellner: Chief Technology Officer (CTO).

• PD Dr. Bettina Nestl: Chief Operating Officer (COO).

• Prof. Karl Gruber: Chief Scientific Officer (CSO).

• Christoph Blaschitz, MSc.: Chief Financial Officer (CFO).

• Dr. Marco Cespugli: Head of Structural Bioinformatics.

• Dr. Bernd Nebel: Senior Scientist and Product/Project Manager.

• Chiara Gasbarri, MSc.: Structural Bioinformatician and Product Specialist.

• Dr. Stefan Grabuschnig: Data Scientist and Solutions Engineer.

• Dr. Michael Hetmann: Structural Bioinformatician and Product Specialist.

Professional Backgrounds and Contributions

• Dr. Christian Gruber (CEO): Leads the company with a focus on strategic direction and innovation.

• Dr. Georg Steinkellner (CTO): Oversees technological development and integration of AI in product offerings.

• PD Dr. Bettina Nestl (COO): Manages operational aspects, ensuring efficient execution of projects.

• Prof. Karl Gruber (CSO): Guides scientific research and development initiatives.

• Christoph Blaschitz, MSc. (CFO): Handles financial strategy and management.

• Dr. Marco Cespugli (Head of Structural Bioinformatics): Leads structural bioinformatics research, contributing to the understanding of protein structures.

• Dr. Bernd Nebel (Senior Scientist and Product/Project Manager): Manages product development and project execution.

• Chiara Gasbarri, MSc. (Structural Bioinformatician and Product Specialist): Specializes in structural bioinformatics and product development.

• Dr. Stefan Grabuschnig (Data Scientist and Solutions Engineer): Focuses on data analysis and engineering solutions.

• Dr. Michael Hetmann (Structural Bioinformatician and Product Specialist): Expert in structural bioinformatics and product specialization.

Competitor Profile

Market Insights and Dynamics

The biotechnology and pharmaceutical sectors are experiencing rapid advancements in AI and machine learning applications, particularly in drug discovery and enzyme engineering. Companies are increasingly seeking innovative solutions to accelerate R&D processes and improve therapeutic outcomes.

Competitor Analysis

• Regor: A biotechnology company focusing on drug discovery and development.

• Ozempic: A pharmaceutical product in the biotechnology industry.

• Trulicity: Another pharmaceutical product within the biotechnology sector.

Strategic Collaborations and Partnerships

Innophore collaborates with industry leaders such as Henkel, Continental, Merck, and leading companies in the flavors and fragrances sector. These partnerships enhance their market position and innovation capacity.

Operational Insights

Innophore's integration of AI with structural biology sets it apart from competitors by offering more precise and efficient solutions in drug discovery and enzyme engineering.